keyword
MENU ▼
Read by QxMD icon Read
search

mCRC

keyword
https://www.readbyqxmd.com/read/28932083/integrating-tyms-kras-and-braf-testing-in-patients-with-metastatic-colorectal-cancer
#1
Anastasios Ntavatzikos, Aris Spathis, Paul Patapis, Nikolaos Machairas, George Peros, Stefanos Konstantoudakis, Danai Leventakou, Ioannis G Panayiotides, Petros Karakitsos, Anna Koumarianou
AIM: To investigate the impact of thymidylate synthase (TYMS), KRAS and BRAF in the survival of metastatic colorectal cancer (mCRC) patients treated with chemotherapy. METHODS: Clinical data were collected retrospectively from records of consecutive patients with mCRC treated with fluoropyrimidine-based chemotherapy from 1/2005 to 1/2007. Formalin-fixed paraffin-embedded tissues were retrieved for analysis. TYMS genotypes were identified with restriction fragment analysis PCR, while KRAS and BRAF mutation status was evaluated using real-time PCR assays...
August 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28927777/the-role-of-cetuximab-in-converting-initially-unresectable-colorectal-cancer-liver-metastases-for-resection
#2
REVIEW
G Poston, R Adam, J Xu, B Byrne, R Esser, H Malik, H Wasan, J Xu
In patients with metastatic colorectal cancer (mCRC) predominantly confined to the liver, whether a patient undergoes potentially curative resection of the liver lesions is a well-established principal determinant of long-term survival. There are a number of different agents, both chemotherapeutic and targeted biologic agents, which can aid in shrinking liver tumors, which would have otherwise been unresectable, allowing for potentially curative resection. The aim of this review article is to summarize the available evidence regarding optimal therapeutic strategies for converting initially unresectable metastases for potentially curative resection; we do not discuss patients who present with initially resectable disease...
August 10, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28923209/angiogenesis-inhibition-in-the-second-line-treatment-of-metastatic-colorectal-cancer-a-systematic-review-and-pooled-analysis
#3
REVIEW
Ralph Chebib, Loic Verlingue, Nathalie Cozic, Matthieu Faron, Pascal Burtin, Valérie Boige, Antoine Hollebecque, David Malka
The last two decades have seen intensive efforts devoted to the development of compounds that target angiogenesis for the treatment of metastatic colorectal cancer (mCRC). In this review, we describe supporting evidence and ongoing development of angiogenesis inhibitors in the second-line treatment of mCRC, and summarize relevant randomized trials to help therapeutic decision-making in daily practice.
April 2017: Seminars in Oncology
https://www.readbyqxmd.com/read/28917269/triplet-folfoxiri-versus-doublet-folfox-or-folfiri-backbone-chemotherapy-as-first-line-treatment-of-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis
#4
REVIEW
Rui Pedro Marques, Gonçalo S Duarte, Carmelo Sterrantino, Helena Luna Pais, António Quintela, Ana Paula Martins, João Costa
Uncertainty exists regarding the comparative effectiveness of triplet chemotherapy (FOLFOXIRI) as backbone first-line chemotherapy for metastatic colorectal cancer (mCRC). We conducted a systematic review and meta-analysis of randomized-controlled trials (RCTs) comparing triplet versus doublet chemotherapy (FOLFOX or FOLFIRI) as first-line therapy in mCRC. Methods and reporting followed PRISMA and SAMPL guidelines. Eight RCTs were included, comprising 1732 patients. In pooled analysis, FOLFOXIRI was associated with improvements in efficacy outcomes, notably with a 25% survival increase (95%CI: 10-37%)...
October 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28911067/maintenance-treatment-with-capecitabine-and-bevacizumab-versus-observation-in-metastatic-colorectal-cancer-updated-results-and-molecular-subgroup-analyses-of-the-phase-3-cairo3-study
#5
K K H Goey, S G Elias, H van Tinteren, M M Laclé, S M Willems, G J A Offerhaus, W W J de Leng, E Strengman, A J Ten Tije, G-J M Creemers, A van der Velden, F E de Jongh, F L G Erdkamp, B C Tanis, C J A Punt, M Koopman
Background: The phase 3 CAIRO3 study showed that capecitabine plus bevacizumab (CAP-B) maintenance treatment after six cycles capecitabine, oxaliplatin, and bevacizumab (CAPOX-B) in metastatic colorectal cancer (mCRC) patients is effective, without compromising quality of life. In this post hoc analysis with updated follow-up and data regarding sidedness, we defined subgroups according to RAS/BRAF mutation status and mismatch repair (MMR) status, and investigated their influence on treatment efficacy...
September 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28906258/early-tumor-shrinkage-indicates-a-favorable-response-to-bevacizumab-based-first-line-chemotherapy-for-metastatic-colorectal-cancer
#6
Mamoru Ito, Hitoshi Kusaba, Satomi Mukaide, Junji Kishimoto, Hozumi Shimokawa, Shingo Tamura, Akitaka Makiyama, Gen Hirano, Hisanobu Oda, Tsuyoshi Shirakawa, Masato Komoda, Keita Uchino, Risa Tanaka, Kenji Mitsugi, Taito Esaki, Shuji Arita, Hiroshi Ariyama, Koichi Akashi, Eishi Baba
A close correlation between early tumor shrinkage (ETS) and overall survival (OS) has been shown in antiepidermal growth factor receptor antibody-based chemotherapies for metastatic colorectal cancer (mCRC), but the clinical impact of ETS in bevacizumab-based chemotherapy has not been adequately clarified. Clinical data of mCRC patients who started initial chemotherapy without antiepidermal growth factor receptor antibody from 2005 to 2010 were retrospectively evaluated. The relative change in tumor size after 8 weeks of chemotherapy expected from the first image assessment [estimated ETS (EETS)] and the relative change in the tumor size at the nadir compared with the baseline [depth of response (DPR)] were examined...
September 12, 2017: Anti-cancer Drugs
https://www.readbyqxmd.com/read/28904173/impact-of-metastasectomy-in-the-multimodality-approach-for-braf-v600e-metastatic-colorectal-cancer-the-mayo-clinic-experience
#7
Benny Johnson, Zhaohui Jin, Mark J Truty, Rory L Smoot, David M Nagorney, Michael L Kendrick, Benjamin R Kipp, Axel Grothey
BACKGROUND: BRAF V600E mutations are present in 8%-10% of patients with metastatic colorectal cancer (mCRC) and portend poor prognosis. This study investigated the impact of metastasectomy for patients with BRAF V600E mCRC. Subjects, Materials, and Methods . Using prospective clinical and molecular data, patients with BRAF V600E mCRC were analyzed for clinical characteristics and survival. Statistical analyses utilized the Kaplan-Meier method, log-rank test, and Cox proportional hazard models...
September 13, 2017: Oncologist
https://www.readbyqxmd.com/read/28903907/research-progress-on-genetic-heterogeneity-between-primary-and-paired-metastatic-colorectal-cancer
#8
You-Wang Lu, Kun-Hua Wang
Colorectal cancer (CRC) is one of the leading causes of cancer deaths in China. A standard practice in treating metastatic CRC (mCRC) is to predict benefits of the anti-EGFR monoclonal antibody treatment based on the somatic mutation spectrum. Because metastatic samples are difficult to obtain clinically, primary tumors are normally used instead. However, due to the genetic heterogeneity between primary and paired metastatic tumors, primary site biopsy always underrepresents the mutational landscape of metastatic sites...
June 20, 2017: Yi Chuan, Hereditas
https://www.readbyqxmd.com/read/28894015/propensity-score-analysis-of-regorafenib-versus-trifluridine-tipiracil-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapy-regotas-a-japanese-society-for-cancer-of-the-colon-and-rectum-multicenter-observational-study
#9
Toshikazu Moriwaki, Shota Fukuoka, Hiroya Taniguchi, Atsuo Takashima, Yusuke Kumekawa, Takeshi Kajiwara, Kentaro Yamazaki, Taito Esaki, Chinatsu Makiyama, Tadamichi Denda, Hironaga Satake, Takeshi Suto, Naotoshi Sugimoto, Masanobu Enomoto, Toshiaki Ishikawa, Tomomi Kashiwada, Masahiko Sugiyama, Yoshito Komatsu, Hiroyuki Okuyama, Eishi Baba, Daisuke Sakai, Tomoki Watanabe, Takao Tamura, Kimihiro Yamashita, Masahiko Gosho, Yasuhiro Shimada
BACKGROUND: This study compared the efficacy of regorafenib and trifluridine/tipiracil (TFTD) in patients with metastatic colorectal cancer (mCRC) who are refractory to standard chemotherapy, because despite their clinical approval, it still remains unclear which of these two drugs should be used as initial treatment. MATERIALS AND METHODS: The clinical data of patients with mCRC who were treated with regorafenib or TFTD and those of drug-naive patients, between June 2014 and September 2015, were retrospectively collected from 24 institutions in Japan...
September 11, 2017: Oncologist
https://www.readbyqxmd.com/read/28884286/combination-of-irinotecan-oxaliplatin-and-5-fluorouracil-as-a-rechallenge-regimen-for-heavily-pretreated-metastatic-colorectal-cancer-patients
#10
Gustavo Dos Santos Fernandes, Maria Ignez Braghiroli, Michelle Artioli, Ana Carolina Carvalho Rocha Paterlini, Marcela Crosara Teixeira, Brenda Pires Gumz, Daniel da Motta Girardi, Oddone F M Braghiroli, Frederico Perego Costa, Paulo M Hoff
PURPOSE: Our objective was to evaluate the benefit of re-exposing patients with refractory metastatic colorectal cancer (mCRC) to a combination of oxaliplatin, irinotecan and 5-fluorouracil treatment. METHODS: We retrospectively analysed patients with mCRC who received a combination of oxaliplatin, irinotecan and fluorouracil as a rechallenge regimen after progressing on the same drugs. Both FOLFOXIRI and FOLFIRINOX were used. Toxicity was evaluated for each treatment cycle, and survival analysis was performed using the Kaplan-Meier method...
September 8, 2017: Journal of Gastrointestinal Cancer
https://www.readbyqxmd.com/read/28881837/the-impact-of-primary-tumor-location-on-efficacy-of-cetuximab-in-metastatic-colorectal-cancer-patients-with-different-kras-status-a-systematic-review-and-meta-analysis
#11
De-Dong Cao, Hui-Lin Xu, Xi-Ming Xu, Wei Ge
OBJECTIVE: To assess the prognostic role of primary tumor location along with Kras status in metastatic colorectal cancer (mCRCs) treated with cetuximab. MATERIALS AND METHODS: Databases of EMBASE, Pubmed, the Cochrane library, China National Knowledge Infrastructure and other databases from inception to July 2016 were searched. Randomized controlled trial (RCT) and/or retrospective studies of influence of primary tumor location on efficacy of cetuximab in patients with mCRC were identified...
August 8, 2017: Oncotarget
https://www.readbyqxmd.com/read/28880972/effect-of-modified-vaccinia-ankara-5t4-and-low-dose-cyclophosphamide-on-antitumor-immunity-in-metastatic-colorectal-cancer-a-randomized-clinical-trial
#12
Martin Scurr, Tom Pembroke, Anja Bloom, David Roberts, Amanda Thomson, Kathryn Smart, Hayley Bridgeman, Richard Adams, Alison Brewster, Robert Jones, Sarah Gwynne, Daniel Blount, Richard Harrop, Melissa Wright, Robert Hills, Awen Gallimore, Andrew Godkin
Importance: The success of immunotherapy with checkpoint inhibitors is not replicated in most cases of colorectal cancer; therefore, different strategies are urgently required. The oncofetal antigen 5T4 is expressed in more than 90% of cases of metastatic colorectal cancer (mCRC). Preliminary data using modified vaccinia Ankara-5T4 (MVA-5T4) in mCRC demonstrated that it safely induced serologic and T-cell responses. Objective: To determine whether antitumor immunity in mCRC could be increased using MVA-5T4, metronomic low-dose cyclophosphamide, or a combination of both treatments...
September 7, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28880238/implications-of-abcg2-expression-on-irinotecan-treatment-of-colorectal-cancer-patients-a-review
#13
REVIEW
Dorte Lisbet Nielsen, Jesper Andreas Palshof, Nils Brünner, Jan Stenvang, Birgitte Martine Viuff
BACKGROUND: One of the main chemotherapeutic drugs used on a routine basis in patients with metastatic colorectal cancer ((m)CRC) is the topoisomerase-1 inhibitor, irinotecan. However, its usefulness is limited by the pre-existing or inevitable development of resistance. The ATP-binding cassette (ABC) transporter ABCG2/breast cancer resistance protein (BRCP) through its function in xenobiotic clearance might play an important role in irinotecan resistance. With a goal to evaluate the clinical significance of ABCG2 measurements, we here review the current literature on ABCG2 in relation to irinotecan treatment in CRC patients...
September 7, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28874891/real-life-treatment-of-metastatic-colorectal-cancer-with-regorafenib-a-single-centre-review
#14
J Gotfrit, M Vickers, S Sud, T Asmis, C Cripps, R Goel, T Hsu, D Jonker, R Goodwin
BACKGROUND: Various tyrosine kinase signalling pathways affect the development and progression of colorectal cancer (crc). In clinical trials, regorafenib has been associated with a survival benefit in metastatic crc (mcrc). We assessed the safety and efficacy of regorafenib in real-world patients. METHODS: In a retrospective review of patients with mcrc treated with regorafenib at our institution from 2013 to 2015, patient demographics, treatment, and survival data were collected...
August 2017: Current Oncology
https://www.readbyqxmd.com/read/28870953/role-of-densitometric-criteria-in-evaluation-of-effectiveness-of-antiangiogenic-therapies-in-metastatic-colorectal-cancer-an-italian-clinical-experience
#15
Giuseppe Cicero, Giuseppe Lo Re, Rossella DE Luca, Federica Vernuccio, Dario Picone, Massimo Midiri, Roberto Lagalla
BACKGROUND/AIM: To evaluate the role of densitometric criterion using the Choi Criteria in the assessment of the response to antiangiogenic treatments of metastatic colorectal cancer (mCRC) compared to the RECIST criteria. PATIENTS AND METHODS: Fifty-four patients (mean age=50.6 years) affected by advanced colorectal cancer and with hepatic and possibly peritoneal and pulmonary metastases, that can be treated with bevacizumab, were prospectively evaluated by computerized tomography (CT) scan...
September 2017: Anticancer Research
https://www.readbyqxmd.com/read/28866662/serum-ca19-9-response-is-an-early-predictive-marker-of-efficacy-of-regorafenib-in-refractory-metastatic-colorectal-cancer
#16
Azusa Komori, Hiroya Taniguchi, Satoshi Hamauchi, Toshiki Masuishi, Yosuke Kito, Yukiya Narita, Takahiro Tsushima, Makoto Ishihara, Akiko Todaka, Tsutomu Tanaka, Tomoya Yokota, Shigenori Kadowaki, Nozomu Machida, Takashi Ura, Akira Fukutomi, Masashi Ando, Yusuke Onozawa, Masahiro Tajika, Hirofumi Yasui, Kei Muro, Keita Mori, Kentaro Yamazaki
PURPOSE: Regorafenib improves survival in chemorefractory metastatic colorectal cancer (mCRC) patients. However, regorafenib induces various adverse events (AEs) that often impair patients' quality of life. Identification of early predictive markers of the efficacy is warranted. METHODS: We retrospectively examined 146 consecutive mCRC patients who received regorafenib. Clinical parameters, including patient background, AEs, and changes in biochemical parameters until day 28, were evaluated to identify efficacy predictors...
September 2, 2017: Oncology
https://www.readbyqxmd.com/read/28855352/low-dose-cyclophosphamide-induces-anti-tumor-t-cell-responses-which-associate-with-survival-in-metastatic-colorectal-cancer
#17
Martin J Scurr, Tom Pembroke, Anja Bloom, David J Roberts, Amanda Thomson, Kathryn Smart, Hayley Bridgeman, Richard A Adams, Alison E Brewster, Robert Jones, Sarah Gwynne, Daniel Blount, Richard Harrop, Robert Hills, Awen Gallimore, Andrew Godkin
PURPOSE: Anti-cancer T-cell responses can control tumors, but immune-suppressive mechanisms in vivo prevent their function. The role of regulatory T-cells (Tregs) in metastatic colorectal cancer (mCRC) is unclear. We have previously shown depletion of Tregs enhances CRC-specific effector T-cell responses. Low dose cyclophosphamide (CPM) targets Tregs in animal models and some human studies, however the effect of CPM in mCRC is unknown. EXPERIMENTAL DESIGN: Fifty-five mCRC patients were enrolled onto a phase I/II trial and randomized to receive two week-long courses of low-dose (50mg twice-a-day) CPM or not...
August 29, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28853050/clinical-pharmacokinetics-and-pharmacodynamics-of-the-epidermal-growth-factor-receptor-inhibitor-panitumumab-in-the-treatment-of-colorectal-cancer
#18
REVIEW
Sander Ketzer, Kirsten Schimmel, Miriam Koopman, Henk-Jan Guchelaar
Despite progress in the treatment of metastatic colorectal cancer (mCRC) in the last 15 years, it is still a condition with a relatively low 5-year survival rate. Panitumumab, a fully human monoclonal antibody directed against the epidermal growth factor receptor (EGFR), is able to prolong survival in patients with mCRC. Panitumumab is used in different lines of therapy in combination with chemotherapy, and as monotherapy for the treatment of wild-type (WT) RAS mCRC. It is administered as an intravenous infusion of 6 mg/kg every 2 weeks and has a t ½ of approximately 7...
August 29, 2017: Clinical Pharmacokinetics
https://www.readbyqxmd.com/read/28844343/inclusion-of-elderly-or-frail-patients-in-randomized-controlled-trials-of-targeted-therapies-for-the-treatment-of-metastatic-colorectal-cancer-a-systematic-review
#19
REVIEW
Amandine Gouverneur, Francesco Salvo, Driss Berdaï, Nicholas Moore, Annie Fourrier-Réglat, Pernelle Noize
Treatment of metastatic colorectal cancer (mCRC) has been modified since the launching of targeted therapies. Colorectal cancer (CRC) is common in elderly patients; their representation in randomized controlled trials (RCTs) is thus crucial. This study aimed to evaluate and quantify the inclusion of elderly/frail patients in RCTs of targeted therapies in mCRC. A systematic review using Medline, Scopus, Cochrane Database and ISI Web of Science was performed to identify all phase II/III RCTs of bevacizumab, cetuximab, panitumumab, regorafenib and aflibercept in mCRC until January 2015...
August 22, 2017: Journal of Geriatric Oncology
https://www.readbyqxmd.com/read/28840585/efficacy-and-safety-of-quxie-capsule-in-metastatic-colorectal-cancer-a-double-blind-randomized-placebo-controlled-trial
#20
Tong Zhang, Yu-Fei Yang, Bin He, Dan-Hui Yi, Jie Hao, Da Zhang
OBJECTIVE: To verify the efficacy and safety of Quxie Capsule () in patients with metastatic colorectal cancer (mCRC). METHODS: The present study was a randomized, double-blind, placebo-controlled trial. Sixty patients with mCRC were randomized into two groups at a 1:1 ratio by sealed envelope. The treatment group received conventional therapy combined with Quxie Capsule for 3 months. The control group was treated with conventional therapy combined with placebo for 3 months...
August 24, 2017: Chinese Journal of Integrative Medicine
keyword
keyword
37091
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"